The Zacks Analyst Blog Novartis, Reddit and Check Point Software TechnologiesZacks Investment Research • 10/29/24
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidanceGlobeNewsWire • 10/29/24
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trialGlobeNewsWire • 10/26/24
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)GlobeNewsWire • 10/24/24
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationZacks Investment Research • 10/21/24
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancerPRNewsWire • 10/18/24
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great MoveThe Motley Fool • 10/17/24